First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer

Purpose: To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval. Methods: PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any...

Descripción completa

Detalles Bibliográficos
Autores: Martinez-Jañez, Noelia|||0000-0002-0436-0906, Bellet Ezquerra, Meritxell|||0000-0001-8859-8307, Manso, Luis|||0000-0002-1683-550X, Carrasco, F.H.|||0000-0003-3819-9572, Torres, A.A.|||0000-0002-9159-4988, Morales, Serafin|||0000-0001-7445-4193, Tolosa, Pablo|||0000-0002-3747-4766, Gil, V.L.O.|||0000-0001-9886-2626, Sampedro, T., Conejero, R.A.|||0000-0003-4315-415X, Calvo-Martinez, L., Galve Calvo, Elena|||0000-0003-4204-5736, López López, Rafael|||0000-0003-1315-655X, de la Pena, F.A.|||0000-0001-6311-920X, Lopez-Tarruella, S.|||0000-0002-2606-9538, de Araguiz, B.A.H.F.|||0000-0001-5650-3502, Ruiz, L.B., Cardenas, T.M., Chacon, J.I., Antón, F.M.|||0000-0001-8933-0687
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:305890
Acceso en línea:https://ddd.uab.cat/record/305890
https://dx.doi.org/urn:doi:10.1007/s10549-024-07287-w
Access Level:acceso abierto
Palabra clave:Advanced breast cancer
First-line treatment
HR+/HER2-
Overall survival
Palbociclib
Progression-free survival
Descripción
Sumario:Purpose: To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval. Methods: PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR/HER2- BC diagnosed between November 2017 and November 2019. The primary endpoint was real-world progression-free survival (rw-PFS). Secondary endpoints included overall survival (OS), the real-world response rate (rw-RR), the clinical benefit rate, palbociclib dose reduction, and safety. Results: A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21-27) and 42 months (40-not estimable [NE]) in the whole population, respectively. By cohort, the median rw-PFS and OS were as follows: 28 (95% CI 23-39) and 44 (95% CI 38-NE) months in patients with de novo metastatic disease, 13 (95% CI 11-17) and 36 months (95% CI 31-41) in patients who experienced relapse < 12 months after the end of ET, and 31 months (95% CI 26-37) and not reached (NR) in patients who experienced relapse.

Similares en LA Referencia